It was reported that a quadrox-id needed to be replaced during treatment due to failing performance.No further information of the patient or perfusion was received.Further return of the involved products was not available.With reference to the quadrox-id risk assessment following probable root causes were determined: air remains in or enters the circuit.Inappropriately low, or no blood flow, in the circuit.Improper hemostasis.Too low anticoagulation.Too low act level, effect of heparin is too limited.Protamine sulfate enters the circuit.Administration of congealable substances (such as platelets) or pro-coagulant medications.(consumption) coagulopathy.The production records of the affected quadrox module were reviewed on 2022-03-30.According to the final test results, all oxygenators passed the tests as per specifications.Production related influences are unlikely to have contributed to the reported failure.Based on the investigation results no product related malfunction could be confirmed.The occurrence rate was calculated for the reported issue and it was determined that this is not a systemic issue.Therefore, no remedial action is required.The occurrence rate related to the reported issue is currently being monitored as part of maquet cardiopulmonary¿ s trending program and additional investigations or corrections will be implemented in case of adverse trending.H3 other text : 4114.
|